A Comparison of Hypofractionated and Twice-Daily Thoracic Irradiation in Limited-Stage Small-Cell Lung Cancer: An Overlap-Weighted Analysis

被引：11

作者：

Yan, Michael ^{[1
]}

Sigurdson, Samantha ^{[1
]}

Greifer, Noah ^{[2
]}

Kennedy, Thomas A. C. ^{[1
]}

Toh, Tzen S. ^{[3
,4
]}

Lindsay, Patricia E. ^{[5
,6
]}

Weiss, Jessica ^{[7
]}

Hueniken, Katrina ^{[4
,7
]}

Yeung, Christy ^{[8
]}

Sugumar, Vijithan ^{[9
]}

Sun, Alexander ^{[5
,6
]}

Bezjak, Andrea ^{[5
,6
]}

Cho, B. C. John ^{[5
,6
]}

Raman, Srinivas ^{[5
,6
]}

Hope, Andrew J. ^{[5
,6
]}

Giuliani, Meredith E. ^{[5
,6
]}

Stuart, Elizabeth A. ^{[2
]}

Owen, Timothy ^{[1
]}

Ashworth, Allison ^{[1
]}

Robinson, Andrew ^{[1
]}

de Moraes, Fabio Ynoe ^{[1
]}

Liu, Geoffrey ^{[4
,10
,11
]}

Lok, Benjamin H. ^{[5
,6
,10
,11
]}

机构：

[1] Queens Univ, Canc Ctr Southeastern Ontario, Dept Oncol, Kingston, ON K7L 5P9, Canada

[2] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD 21205 USA

[3] Univ Sheffield, Med Sch, Sheffield S10 2RX, S Yorkshire, England

[4] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada

[5] Princess Margaret Canc Ctr, Radiat Med Program, Toronto, ON M5G 2M9, Canada

[6] Univ Toronto, Dept Radiat Oncol, Toronto, ON M5T 1P5, Canada

[7] Princess Margaret Canc Ctr, Dept Biostat, Toronto, ON M5G 2M9, Canada

[8] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 0A4, Canada

[9] Western Univ, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada

[10] Univ Toronto, Fac Med, Inst Med Sci, Toronto, ON M5S 1A8, Canada

[11] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L7, Canada

来源：

CANCERS | 2021年 / 13卷 / 12期

基金：

加拿大创新基金会; 加拿大健康研究院;

关键词：

small-cell lung cancer; hypofractionation; radiotherapy; propensity score; OPEN-LABEL; RADIOTHERAPY; RADIATION; CHEMOTHERAPY; MANAGEMENT; SURVIVAL; FRACTIONATION; REPOPULATION; OUTCOMES; IMPACT;

D O I：

10.3390/cancers13122895

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary The optimal thoracic radiotherapy schedule for limited-stage small cell lung cancer (LS-SCLC) patients remains controversial. We conducted a propensity score adjusted analysis of LS-SCLC patients treated at our institutions with 40Gy/15 fractions versus 45Gy/30 twice daily. After overlap weighting for clinical and treatment variables and attaining good balance, we did not find a significant difference in overall survival, locoregional recurrence risk, thoracic response, or >= grade 3 toxicity. Moderate hypofractionation, with its similar outcomes and logistical advantages, may present a reasonable alternative to twice daily radiotherapy. Despite evidence for the superiority of twice-daily (BID) radiotherapy schedules, their utilization in practice remains logistically challenging. Hypofractionation (HFRT) is a commonly implemented alternative. We aim to compare the outcomes and toxicities in limited-stage small-cell lung cancer (LS-SCLC) patients treated with hypofractionated versus BID schedules. A bi-institutional retrospective cohort review was conducted of LS-SCLC patients treated with BID (45 Gy/30 fractions) or HFRT (40 Gy/15 fractions) schedules from 2007 to 2019. Overlap weighting using propensity scores was performed to balance observed covariates between the two radiotherapy schedule groups. Effect estimates of radiotherapy schedule on overall survival (OS), locoregional recurrence (LRR) risk, thoracic response, any >= grade 3 (including lung, and esophageal) toxicity were determined using multivariable regression modelling. A total of 173 patients were included in the overlap-weighted analysis, with 110 patients having received BID treatment, and 63 treated by HFRT. The median follow-up was 20.4 months. Multivariable regression modelling did not reveal any significant differences in OS (hazard ratio [HR] 1.67, p = 0.38), LRR risk (HR 1.48, p = 0.38), thoracic response (odds ratio [OR] 0.23, p = 0.21), any >= grade 3+ toxicity (OR 1.67, p = 0.33), >= grade 3 pneumonitis (OR 1.14, p = 0.84), or >= grade 3 esophagitis (OR 1.41, p = 0.62). HFRT, in comparison to BID radiotherapy schedules, does not appear to result in significantly different survival, locoregional control, or toxicity outcomes.

引用

页数：16

共 42 条

[1] A retrospective analysis of survival outcomes for two different radiotherapy fractionation schedules given in the same overall time for limited stage small cell lung cancer [J].

Bettington, Catherine S. ;

Tripcony, Lee ;

Bryant, Guy ;

Hickey, Brigid ;

Pratt, Gary ;

Fay, Michael .

JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2013, 57 (01) :105-112

[2] Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: Repopulation as a cause of treatment failure? [J].

Brade, AM ;

Tannock, IF .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1020-1022

[3] Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer [J].

De Ruysscher, D ;

Pijls-Johannesma, M ;

Bentzen, SM ;

Minken, A ;

Wanders, R ;

Lutgens, L ;

Hochstenbag, M ;

Boersma, L ;

Wouters, B ;

Lammering, G ;

Vansteenkiste, J ;

Lambin, P .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1057-1063

[4] Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysisaEuro [J].

De Ruysscher, D. ;

Lueza, B. ;

Le Pechoux, C. ;

Johnson, D. H. ;

O'Brien, M. ;

Murray, N. ;

Spiro, S. ;

Wang, X. ;

Takada, M. ;

Lebeau, B. ;

Blackstock, W. ;

Skarlos, D. ;

Baas, P. ;

Choy, H. ;

Price, A. ;

Seymour, L. ;

Arriagada, R. ;

Pignon, J. -P. .

ANNALS OF ONCOLOGY, 2016, 27 (10) :1818-1828

[5] Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial [J].

Faivre-Finn, Corinne ;

Snee, Michael ;

Ashcroft, Linda ;

Appel, Wiebke ;

Barlesi, Fabrice ;

Bhatnagar, Adityanarayan ;

Bezjak, Andrea ;

Cardenal, Felipe ;

Fournel, Pierre ;

Harden, Susan ;

Le Pechoux, Cecile ;

McMenemin, Rhona ;

Mohammed, Nazia ;

O'Brien, Mary ;

Pantarotto, Jason ;

Surmont, Veerle ;

Van Meerbeeck, Jan P. ;

Woll, Penella J. ;

Lorigan, Paul ;

Blackhall, Fiona .

LANCET ONCOLOGY, 2017, 18 (08) :1116-1125

[6] Radiation Dose and Fractionation for Limited-stage Small-cell Lung Cancer: Survey of US Radiation Oncologists on Practice Patterns [J].

Farrell, Matthew J. ;

Yahya, Jehan B. ;

Degnin, Catherine ;

Chen, Yiyi ;

Holland, John M. ;

Henderson, Mark A. ;

Jaboin, Jerry J. ;

Harkenrider, Matthew M. ;

Thomas, Charles R., Jr. ;

Mitin, Timur .

CLINICAL LUNG CANCER, 2019, 20 (01) :13-19

[7] A proportional hazards model for the subdistribution of a competing risk [J].

Fine, JP ;

Gray, RJ .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) :496-509

[8] Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer - Decision criteria in routine practise [J].

Glatzer, Markus ;

Faivre-Finn, Corinne ;

De Ruysscher, Dirk ;

Widder, Joachim ;

Van Houtte, Paul ;

Troost, Esther G. C. ;

Dahele, M. R. ;

Slotman, Ben J. ;

Ramella, Sara ;

Poettgen, Christoph ;

Peeters, Stephanie T. H. ;

Nestle, Ursula ;

McDonald, Fiona ;

Le Pechoux, Cecile ;

Dziadziuszko, Rafal ;

Belderbos, Jose ;

Putora, Paul M. .

RADIOTHERAPY AND ONCOLOGY, 2020, 150 :26-29

[9] Missing Data Analysis: Making It Work in the Real World [J].

Graham, John W. .

ANNUAL REVIEW OF PSYCHOLOGY, 2009, 60 :549-576

[10] Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer [J].

Gronberg, Bjorn H. ;

Halvorsen, Tarje O. ;

Flotten, Oystein ;

Brustugun, Odd T. ;

Brunsvig, Paal F. ;

Aasebo, Ulf ;

Bremnes, Roy M. ;

Tollali, Terje ;

Hornslien, Kjersti ;

Aksnessaether, Bjorg Y. ;

Liaaen, Erik D. ;

Sundstrom, Stein .

ACTA ONCOLOGICA, 2016, 55 (05) :591-597

← 1 2 3 4 5 →